SCPH scPharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: SCPH

Price (delayed)

$4.66

Market cap

$168.01M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.42

Enterprise value

$161.47M

scPharmaceuticals is a pharmaceutical company focused on developing and commercializing products that are designed to reduce healthcare costs and improve health outcomes. The Company develops, internally and through strategic partnerships, ...

Highlights
The revenue has surged by 81% since the previous quarter
scPharmaceuticals's gross profit has surged by 79% QoQ
The company's quick ratio has shrunk by 62% YoY and by 29% QoQ
scPharmaceuticals's net income has decreased by 49% YoY and by 9% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.scpharmaceuticals.com
Peers: OPTN OPK ORGO

Key stats

What are the main financial stats of SCPH
Market
Shares outstanding
36.05M
Market cap
$168.01M
Enterprise value
$161.47M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.49
Price to sales (P/S)
13.2
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.88
Earnings
Revenue
$13.59M
EBIT
-$46.69M
EBITDA
-$46.06M
Free cash flow
-$59.28M
Per share
EPS
-$1.42
Free cash flow per share
-$1.54
Book value per share
$1.04
Revenue per share
$0.35
TBVPS
$2.45
Balance sheet
Total assets
$94.48M
Total liabilities
$57.26M
Debt
$40.27M
Equity
$37.22M
Working capital
$79.8M
Liquidity
Debt to equity
1.08
Current ratio
7.08
Quick ratio
6.13
Net debt/EBITDA
0.14
Margins
EBITDA margin
-338.9%
Gross margin
72%
Net margin
-403.2%
Operating margin
-407.5%
Efficiency
Return on assets
-49.6%
Return on equity
-97.2%
Return on invested capital
-56.5%
Return on capital employed
-57.4%
Return on sales
-343.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

SCPH stock price

How has the scPharmaceuticals stock price performed over time
Intraday
0%
1 week
3.79%
1 month
-10.56%
1 year
-57.05%
YTD
-25.68%
QTD
-7.17%

Financial performance

How have scPharmaceuticals's revenue and profit performed over time
Revenue
$13.59M
Gross profit
$9.78M
Operating income
-$55.4M
Net income
-$54.81M
Gross margin
72%
Net margin
-403.2%
The revenue has surged by 81% since the previous quarter
scPharmaceuticals's gross profit has surged by 79% QoQ
scPharmaceuticals's operating income has shrunk by 53% YoY and by 12% QoQ
scPharmaceuticals's net income has decreased by 49% YoY and by 9% QoQ

Growth

What is scPharmaceuticals's growth rate over time

Valuation

What is scPharmaceuticals stock price valuation
P/E
N/A
P/B
4.49
P/S
13.2
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.88
The company's EPS fell by 9% YoY and by 4.4% QoQ
The equity has contracted by 49% YoY and by 24% from the previous quarter
The price to book (P/B) is 45% more than the 5-year quarterly average of 3.1 but 15% less than the last 4 quarters average of 5.3
SCPH's price to sales (P/S) is 84% lower than its last 4 quarters average of 81.8
The revenue has surged by 81% since the previous quarter

Efficiency

How efficient is scPharmaceuticals business performance
scPharmaceuticals's return on invested capital has surged by 51% YoY but it has decreased by 13% QoQ
The company's return on sales rose by 39% QoQ
SCPH's ROE is down by 28% year-on-year and by 26% since the previous quarter
The return on assets has declined by 16% since the previous quarter

Dividends

What is SCPH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SCPH.

Financial health

How did scPharmaceuticals financials performed over time
The company's total assets is 65% higher than its total liabilities
The company's quick ratio has shrunk by 62% YoY and by 29% QoQ
The current ratio has plunged by 57% YoY and by 26% from the previous quarter
SCPH's debt is 8% higher than its equity
SCPH's debt to equity has surged by 108% year-on-year and by 33% since the previous quarter
The equity has contracted by 49% YoY and by 24% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.